Literature DB >> 29697285

Grading Severity of Productive Cough Based on Symptoms and Airflow Obstruction.

Rodrigo Vazquez Guillamet1, Hans Petersen2, Paula Meek3, Akshay Sood1, Yohannes Tesfaigzi2.   

Abstract

The binary approach to the diagnosis of Chronic Bronchitis (CB) is a major barrier to the study of the disease. We investigated whether severity of productive cough can be graded using symptoms and presence of fixed airflow obstruction (FAO), and whether the severity correlates with health status, exposures injurious to the lung, biomarkers of inflammation, and measures of airway wall thickening. Findings from a cross-sectional sample of 1,422 participants from the Lovelace Smokers Cohort (LSC) were validated in 4,488 participants from the COPDGene cohort (COPDGene). Health status was based on the St. George's Respiratory Questionnaire, and Medical Outcomes Study 36-Item Short Form Health Survey. Circulating CC16 levels were quantified by ELISA (LSC), and airway wall thickening was measured using computed tomography (COPDGene). FAO was defined as postbronchodilator FEV1/FVC <0.7. The presence and duration of productive cough and presence of FAO or wheeze were graded into Healthy Smokers, Productive Cough (PC), Chronic PC, PC with Signs of Airflow Obstruction, and Chronic PC with Signs of Airflow Obstruction. In both cohorts, higher grade of severity correlated with lower health status, greater frequency of injurious exposures, greater airway wall thickening, and lower circulating CC16 levels. Further, longitudinal follow-up suggested that disease resolution can occur at every grade of severity but is more common in groups of lower severity and least common once airway remodeling develops. Therefore, severity of productive cough can be graded based on symptoms and FAO and early intervention may benefit patients by changing the natural history of disease.

Entities:  

Keywords:  Chronic bronchitis; radiographic measures of airway remodeling; severity stages; symptom scores; wheeze

Mesh:

Substances:

Year:  2018        PMID: 29697285      PMCID: PMC6239864          DOI: 10.1080/15412555.2018.1458218

Source DB:  PubMed          Journal:  COPD        ISSN: 1541-2563            Impact factor:   2.409


  42 in total

1.  The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study.

Authors:  Maria Montes de Oca; Ronald J Halbert; Maria Victorina Lopez; Rogelio Perez-Padilla; Carlos Tálamo; Dolores Moreno; Adrianna Muiño; José Roberto B Jardim; Gonzalo Valdivia; Julio Pertuzé; Ana Maria B Menezes
Journal:  Eur Respir J       Date:  2012-01-26       Impact factor: 16.671

2.  Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters.

Authors:  A B Thompson; D Daughton; R A Robbins; M A Ghafouri; M Oehlerking; S I Rennard
Journal:  Am Rev Respir Dis       Date:  1989-12

3.  Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers.

Authors:  Akshay Sood; Hans Petersen; Christopher M Blanchette; Paula Meek; Maria A Picchi; Steven A Belinsky; Yohannes Tesfaigzi
Journal:  Am J Respir Crit Care Med       Date:  2010-07-01       Impact factor: 21.405

4.  Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use.

Authors:  Hans Petersen; Akshay Sood; Paula M Meek; Xian Shen; Yan Cheng; Steven A Belinsky; Caroline A Owen; George Washko; Victor Pinto-Plata; Emer Kelly; Bartolome Celli; Yohannes Tesfaigzi
Journal:  Chest       Date:  2014-04       Impact factor: 9.410

5.  Heredity of chronic bronchitis: a registry-based twin study.

Authors:  Howraman Meteran; Vibeke Backer; Kirsten Ohm Kyvik; Axel Skytthe; Simon Francis Thomsen
Journal:  Respir Med       Date:  2014-07-04       Impact factor: 3.415

6.  Chronic bronchitis in the general population: influence of age, gender and socio-economic conditions.

Authors:  Alexis Ferré; Claire Fuhrman; Mahmoud Zureik; Christos Chouaid; Alain Vergnenègre; Gérard Huchon; Marie-Christine Delmas; Nicolas Roche
Journal:  Respir Med       Date:  2011-12-23       Impact factor: 3.415

7.  Protective role for club cell secretory protein-16 (CC16) in the development of COPD.

Authors:  Maria E Laucho-Contreras; Francesca Polverino; Kushagra Gupta; Katherine L Taylor; Emer Kelly; Victor Pinto-Plata; Miguel Divo; Naveed Ashfaq; Hans Petersen; Barry Stripp; Aprile L Pilon; Yohannes Tesfaigzi; Bartolome R Celli; Caroline A Owen
Journal:  Eur Respir J       Date:  2015-02-19       Impact factor: 16.671

8.  Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers.

Authors:  B W M Willemse; N H T ten Hacken; B Rutgers; I G A T Lesman-Leegte; D S Postma; W Timens
Journal:  Eur Respir J       Date:  2005-11       Impact factor: 16.671

9.  Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.

Authors:  Jadwiga A Wedzicha; Donald Banerji; Kenneth R Chapman; Jørgen Vestbo; Nicolas Roche; R Timothy Ayers; Chau Thach; Robert Fogel; Francesco Patalano; Claus F Vogelmeier
Journal:  N Engl J Med       Date:  2016-05-15       Impact factor: 91.245

10.  Spirometric variability in smokers: transitions in COPD diagnosis in a five-year longitudinal study.

Authors:  Akshay Sood; Hans Petersen; Clifford Qualls; Paula M Meek; Rodrigo Vazquez-Guillamet; Bartolome R Celli; Yohannes Tesfaigzi
Journal:  Respir Res       Date:  2016-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.